Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
about
Review article: dermatological complications of immunosuppressive and anti-TNF therapy in inflammatory bowel diseaseBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisThe effect of targeted rheumatoid arthritis therapies on anti-citrullinated protein autoantibody levels and B cell responsesWhat is the utility of routine ANA testing in predicting development of biological DMARD-induced lupus and vasculitis in patients with rheumatoid arthritis? Data from a single-centre cohort.Observational study on efficacy, safety, and drug survival of anakinra in rheumatoid arthritis patients in clinical practice.Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome.Tumor necrosis factor inhibitor-associated dermatomyositisLupus serum IgG induces skin inflammation through the TNFR1 signaling pathwayHemophagocytic syndrome occurring in an adult liver transplant recipient having Still's disease.Long-term use of adalimumab in the treatment of moderate to severe plaque psoriasis: a review of the literature.Adalimumab clinical efficacy is associated with rheumatoid factor and anti-cyclic citrullinated peptide antibody titer reduction: a one-year prospective study.Current state of tumour necrosis factor {alpha} blockade in Wegener's granulomatosis.Updated consensus statement on biological agents, specifically tumour necrosis factor {alpha} (TNF{alpha}) blocking agents and interleukin-1 receptor antagonist (IL-1ra), for the treatment of rheumatic diseases, 2005Predictors of infusion reactions during infliximab treatment in patients with arthritis.Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006.Onset of lupus like syndrome in patients with spondyloarthritis treated with anti-TNF-α.Drug-induced glomerular disease: immune-mediated injury.Correlation of antinuclear antibody and anti-double-stranded DNA antibody with clinical response to infliximab in patients with rheumatoid arthritis: a retrospective clinical study.Autoimmunogenicity during anti-TNF therapy in patients with psoriasis and psoriatic arthritisUpdated consensus statement on biological agents for the treatment of rheumatic diseases, 2007The effect of TNFalpha blockade on the antinuclear antibody profile in patients with chronic arthritis: biological and clinical implications.The impact of biological treatments on the anti-dsDNA and anti-nucleosome tests.Anti-Tumor Necrosis Factor-α Induced Systemic Lupus Erythematosus().TNFalpha blockade in human diseases: an overview of efficacy and safety.Drug-induced lupus erythematosus with emphasis on skin manifestations and the role of anti-TNFα agentsThe role of tumor necrosis factor-alpha in systemic lupus erythematosusLessons for lupus from tumour necrosis factor blockade.Adalimumab for rheumatoid arthritis.Autoantibody production in anti-TNF-alpha-treated patients.The skin tissue is adversely affected by TNF-alpha blockers in patients with chronic inflammatory arthritis: a 5-year prospective analysis.Efficacy, safety and patient-reported outcomes of combination etanercept and sulfasalazine versus etanercept alone in patients with rheumatoid arthritis: a double-blind randomised 2-year study.Etanercept-induced systemic lupus erythematosus in a patient with rheumatoid arthritis.The changing face of spondyloarthropathies under TNF α blockade.Efficacy of abatacept for arthritis in patients with an overlap syndrome between rheumatoid arthritis and systemic lupus erythematosus.Cardiac Tamponade as a Presenting Manifestation of Infliximab-Induced Lupus in Patient Treated for Crohn's Disease.TNF alpha antagonist-induced lupus-like syndrome: report and review of the literature with implications for treatment with alternative TNF alpha antagonists.Drug-induced lupus erythematosus: incidence, management and prevention.Adalimumab: a review of its use in the treatment of patients with ulcerative colitis.Systematic review of infliximab-induced autoantibodies and systemic lupus erythematosus.Immune-mediated inflammatory reactions and tumors as skin side effects of inflammatory bowel disease therapy.
P2860
Q26822029-01F03043-EDED-4A66-9177-30509569319CQ26852235-8EF1D0BD-F974-43E5-9EBA-2BDBA9F7EED9Q27022645-79923C8D-9CA6-49C8-8E36-107E5D88A242Q30826279-D442F4CC-3A90-4B25-8946-7980898DB5EAQ33369142-A4816239-73AC-489D-A0B6-CAE9D5FB3F21Q33737258-349504C2-270F-4BCD-AD9E-8CF7D734E968Q34015824-2D1C4615-2528-4AB2-B74E-E276B581B6CDQ34080126-49F9EB38-B066-443E-8F94-6458EE685850Q34553515-EF2BAA96-22FB-494C-8821-5F7B0D1AA710Q34620323-DC0ABEA9-7987-4BCD-ACF2-6A131FB36164Q34896439-234203BC-2662-4421-85ED-24B2D330439FQ35579503-879C95BE-0133-415F-8619-881F1B355576Q35579517-823E58B5-44BE-4B43-971B-34F5C28FF5B5Q35605532-ED15E368-B0CD-408C-90F8-3C869A697FDCQ35638252-710FB781-23D6-4A65-B6B7-F9ABC664BC33Q35808834-8AD264D2-8AF4-4BF6-B06A-EDCE2BFB12B6Q35816996-CDB2921A-F2CF-4A41-9FF7-BA01ACB2F6E7Q35907845-A48AEFD9-CE40-4CF6-90E4-358A69DCDCB9Q36048476-CDC0D3B0-D4D2-4108-81D7-202F6AA060A9Q36171750-E45E46FB-62C5-4C29-A6B2-AAC4D520B485Q36373315-20545C06-57DD-4FCE-96D6-586A7983E3E4Q36394266-D2835661-5725-426D-8DCD-414C227666E8Q36418745-68D6F555-C7ED-4BBF-B446-8F37B6D0FA52Q36536861-8167BD4D-E42C-430C-BEB6-11E77B6D0674Q36579988-36C383A5-4A11-44A2-B34C-2AD6EED5145CQ36641608-6B2C1252-4421-40CD-B20D-2ED7939E4AEFQ36677012-B8C01227-837A-46F4-97A6-C33AB06F48E7Q36708319-1FE10D83-BD44-4CEC-A898-5B9C9C7AE4C0Q36958337-30B01158-F8DD-4A75-8080-75FCFF11EA01Q37196596-6CDD294C-78D1-4093-A2DA-54503DA0C3AFQ37210207-2D07EE3B-1B77-48FF-98C2-7CB99033905AQ37292333-D8F9CD18-F028-4F75-AC8B-F45F2B8C58DEQ37352654-0A0A2805-59A6-450C-B1AA-BF269BFF1BCEQ37353822-FE3111BE-02D5-4C49-9C9F-3FD73AAF4A01Q37593973-092832E6-3EE9-4C00-B85F-2B4B4DFEE9F0Q37867162-02953B57-31BF-4748-9090-AECCD351BEC5Q37868002-F21F82F9-85EC-41B9-81A9-9666E560A03CQ38098468-D3F842F6-C5AE-480C-B197-630EBF8180EDQ38161813-31698249-1385-4CF9-95EE-385DDA8AABAEQ38179468-CFA12189-896D-4064-A4AD-556F80DC4CDA
P2860
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
description
2004 nî lūn-bûn
@nan
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
2004年论文
@zh
2004年论文
@zh-cn
name
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@ast
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@en
type
label
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@ast
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@en
prefLabel
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@ast
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@en
P2093
P2860
P356
P1476
Autoantibody formation in patients with rheumatoid arthritis treated with anti-TNF alpha.
@en
P2093
Engstrand S
Eriksson C
Rantapää-Dahlqvist S
Sundqvist KG
P2860
P304
P356
10.1136/ARD.2004.024182
P407
P577
2004-08-05T00:00:00Z